We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck, Ridgeback Starting Phase 3 Trial of COVID-19 Preventative
Merck, Ridgeback Starting Phase 3 Trial of COVID-19 Preventative
Merck and Miami, Fla.-based Ridgeback Biotherapeutics are starting a phase 3 clinical trial of molnupiravir, which is intended to stop infection with COVID-19 after a person has been exposed.